Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
...bally. Patients were randomized to receive either 6.0 mg/kg of Vectibix and folfox4
once every two weeks (Q2W) or folfox4
alone Q2W. The primary endpoint of the study is progression-free survival b...
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
...ears, Stage III colon cancer patients treated with folfox4
had a 20
percent reduction in the risk of dying co...ripheral sensory neuropathy. Patients
treated with folfox4
also reported nausea (73.7%), diarrhea (56.3%) and...omized to treatment with either the
regimen (n=1,123) or standard chemotherapy 5-FU/LV...
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
... patients treated in the EPOC study,
chemotherapy and surgery significantly improved PF...iver metastases, post-entry
(n=303), perioperative folfox4
significantly improved PFS by 9.2% (from
33.2% to ...ound that the investigational use of
reduces the risk of relapse by one fourth over
Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
...by fever or infection in
only 1.8% of cases. 92.1% of patients treated with folfox4
sensory neuropathy ("tingling or numbness" in the fingers or...rved in most cases
within 18 months following treatment. Patients receiving folfox4
reported nausea (73.7%), diarrhea (56.3%) and vomiting (47.2%).
The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved
Progression Free Survival When Given Before and After Surgery in
Patients With Resectable Liver Metastases From Colorectal Cancer
...st time that peri-operative (pre and post
(Eloxatin(R) (oxaliplatin injection) in
At a median follow-up of three years, folfox4
before and after surgery significa...tients (171 in each arm), even those not
treatment significantly improved PFS by 8.1% and
Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New
Treatment Benchmark in Patients With Metastatic Colorectal Cancer
Chemotherapy Results in Improved Long-term [Five-y...tic (advanced) colorectal cancer.
Importantly, the folfox4
results were significantly better than
those achie...icago in an updated
analysis of the N9741 study.
(Eloxatin(R) combined with infusional 5-FU/LV) was...